-- Dr. Jacobson recognized for his pioneering
work in nonsense-mediated mRNA decay --
SOUTH
PLAINFIELD, N.J., July 19,
2023 /PRNewswire/ -- PTC Therapeutics, Inc.
(NASDAQ: PTCT) today announced that Allan
Jacobson, Ph.D., co-founder of PTC and member of the Board
of Directors, was presented the 2023 Gruber Genetics Prize for his
work in identifying and describing the mechanism of
nonsense-mediated mRNA decay today in a ceremony in Australia.
"On behalf of PTC's Board of Directors and leadership team we
congratulate Allan on receiving this prestigious award and
recognition," said Matthew B. Klein,
M.D., Chief Executive Officer, PTC Therapeutics. "Allan's
incredibly important work has led to meaningful advances in the
treatment of rare diseases including Translarna which was
foundational in the success of PTC."
The Gruber International Prize Program honors individuals in the
fields of Cosmology, Genetics and Neuroscience, whose
groundbreaking work provides new models that inspire and enable
fundamental shifts in knowledge and culture. Dr. Jacobson shares
the prize with Lynn Maquat, Ph.D., a
molecular biologist at the University of
Rochester School of Medicine and Dentistry.
About PTC Therapeutics, Inc.
PTC is a global
biopharmaceutical company focused on the discovery, development and
commercialization of clinically differentiated medicines that
provide benefits to patients with rare disorders. PTC's ability to
innovate to identify new therapies and to globally commercialize
products is the foundation that drives investment in a robust and
diversified pipeline of transformative medicines. PTC's mission is
to provide access to best-in-class treatments for patients who have
little to no treatment options. PTC's strategy is to leverage its
strong scientific and clinical expertise and global commercial
infrastructure to bring therapies to patients. PTC believes this
allows it to maximize value for all its stakeholders. To learn more
about PTC, please visit us at www.ptcbio.com and follow us on
Facebook, Instagram, LinkedIn and Twitter at @PTCBio.
For More Information:
Investors:
Kylie
O'Keefe
+1 (908) 300-0691
kokeefe@ptcbio.com
Media:
Jeanine
Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original
content:https://www.prnewswire.com/news-releases/ptc-therapeutics-co-founder-allan-jacobson-phd-awarded-2023-gruber-genetics-prize-301881416.html
SOURCE PTC Therapeutics